Amgen To Invest In Israel-Based eHealth Ventures Read more about Amgen To Invest In Israel-Based eHealth Ventures
Amgen Announces Webcast Of 2016 Third Quarter Financial Results Read more about Amgen Announces Webcast Of 2016 Third Quarter Financial Results
Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients Read more about Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients
Amgen Announces 2016 Fourth Quarter Dividend Read more about Amgen Announces 2016 Fourth Quarter Dividend
Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors Read more about Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin Read more about New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin
New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress Read more about New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress
Amgen To Participate In Citi Biotech R&D Conference Call Read more about Amgen To Participate In Citi Biotech R&D Conference Call
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations Read more about Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study Read more about Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
